{
  "data": [
    {
      "studyid_add": "ARGX-113-2009",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "bp",
      "study": "argx-113-2009",
      "sdtm_ae_refresh_date": "2024-10-29",
      "adsl_refresh_date": "2024-10-29",
      "Trial_Title": "A PHASE 2/3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF EFGARTIGIMOD PH20 SC IN ADULT PARTICIPANTS WITH BULLOUS PEMPHIGOID",
      "No_of_subjects_treated": 98,
      "First_ICF_date": "2022-06-22",
      "eosdt": "2024-09-13",
      "lstcndt": "2024-09-13",
      "FPFV": "2022-06-09",
      "LPLV": "2024-09-13",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.5",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-2009",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "BALLAD",
      "Last_Achieved_Milestone": "LSLV",
      "Last_Achieved_Milestones_Long": "Last Subject Last Visit",
      "protocol_name": "A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid",
      "days_since_last_adsl_refresh": 0,
      "days_since_last_ae_refresh": 0,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": "2024-10-27",
      "EDC_extract_min_dt": "2024-10-27"
    },
    {
      "studyid_add": "ARGX-113-2010",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "bp",
      "study": "argx-113-2010",
      "sdtm_ae_refresh_date": "2024-10-29",
      "adsl_refresh_date": "2024-10-29",
      "Trial_Title": "AN OPEN-LABEL EXTENSION STUDY OF ARGX-113-2009 TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD PH20 SC IN ADULT PARTICIPANTS WITH BULLOUS PEMPHIGOID",
      "No_of_subjects_treated": 49,
      "First_ICF_date": "2023-03-22",
      "eosdt": "2024-10-18",
      "lstcndt": "2024-10-25",
      "FPFV": "2023-03-22",
      "LPLV": "2024-10-25",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "1",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2010",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "BALLAD +",
      "Last_Achieved_Milestone": "LSFV",
      "Last_Achieved_Milestones_Long": "Last Subject First Visit",
      "protocol_name": "An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid",
      "days_since_last_adsl_refresh": 0,
      "days_since_last_ae_refresh": 0,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": "2024-10-27",
      "EDC_extract_min_dt": "2024-10-27"
    },
    {
      "studyid_add": "ARGX-113-1902",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "cidp",
      "study": "argx-113-1902",
      "sdtm_ae_refresh_date": "2024-10-22",
      "adsl_refresh_date": "2024-10-23",
      "Trial_Title": "OPEN-LABEL EXTENSION OF THE ARGX-113-1802 TRIAL TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD PH20 SC IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)",
      "No_of_subjects_treated": 228,
      "First_ICF_date": "2020-09-17",
      "eosdt": "2024-09-17",
      "lstcndt": "2024-10-04",
      "FPFV": "2020-09-17",
      "LPLV": "2024-10-02",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-1902",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "ADHERE+",
      "Last_Achieved_Milestone": "LSFV",
      "Last_Achieved_Milestones_Long": "Last Subject First Visit",
      "protocol_name": "Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "days_since_last_adsl_refresh": 6,
      "days_since_last_ae_refresh": 7,
      "days_between": 1,
      "ord": 1,
      "ae_refresh_dt": "2024-09-10",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "iim",
      "study": "argx-113-2007",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "A PHASE 2/3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 2-ARM, MULTICENTER, OPERATIONALLY SEAMLESS STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACODYNAMICS, PHARMACOKINETICS, AND IMMUNOGENICITY OF EFGARTIGIMOD PH20 SC IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHY",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "ALKIVIA",
      "Last_Achieved_Milestone": "FSFV",
      "Last_Achieved_Milestones_Long": "First Subject First Visit",
      "protocol_name": "A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 1,
      "ae_refresh_dt": "2024-10-15",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2011",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "iim",
      "study": "argx-113-2011",
      "sdtm_ae_refresh_date": "2024-10-29",
      "adsl_refresh_date": "2024-10-29",
      "Trial_Title": "A PHASE 3, SINGLE-ARM, MULTICENTER, OPEN-LABEL EXTENSION OF STUDY ARGX-113-2007 TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD PH20 SC IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHY",
      "No_of_subjects_treated": 69,
      "First_ICF_date": "2023-09-12",
      "eosdt": "2024-09-18",
      "lstcndt": "2024-10-23",
      "FPFV": "2023-09-12",
      "LPLV": "2024-10-28",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2011",
      "Investigational_Treatment": "HYALURONIDASE (HUMAN RECOMBINANT) 743QUY4VD8",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "ALKIVIA+",
      "Last_Achieved_Milestone": "FSFV",
      "Last_Achieved_Milestones_Long": "First Subject First Visit",
      "protocol_name": "A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy",
      "days_since_last_adsl_refresh": 0,
      "days_since_last_ae_refresh": 0,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": "2024-10-27",
      "EDC_extract_min_dt": "2024-10-27"
    },
    {
      "studyid_add": "ARGX-113-1803",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "itp",
      "study": "argx-113-1803",
      "sdtm_ae_refresh_date": "2024-10-24",
      "adsl_refresh_date": "2024-10-05",
      "Trial_Title": "A PHASE 3, MULTICENTER, OPEN-LABEL, LONG-TERM TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF EFGARTIGIMOD (ARGX-113) 10 MG/KG INTRAVENOUS IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA.",
      "No_of_subjects_treated": 101,
      "First_ICF_date": "2020-06-02",
      "eosdt": "2024-06-11",
      "lstcndt": "2024-09-26",
      "FPFV": "2002-09-04",
      "LPLV": "2024-09-26",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-1803",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "ADVANCE+",
      "Last_Achieved_Milestone": "LSFV",
      "Last_Achieved_Milestones_Long": "Last Subject First Visit",
      "protocol_name": "A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia",
      "days_since_last_adsl_refresh": 24,
      "days_since_last_ae_refresh": 5,
      "days_between": -19,
      "ord": 1,
      "ae_refresh_dt": "2024-10-08",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2005",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "itp",
      "study": "argx-113-2005",
      "sdtm_ae_refresh_date": "2024-10-24",
      "adsl_refresh_date": "2024-10-05",
      "Trial_Title": "A PHASE 3, MULTICENTER, OPEN-LABEL, LONG-TERM TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF EFGARTIGIMOD (ARGX-113) PH20 SUBCUTANEOUS IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA",
      "No_of_subjects_treated": 173,
      "First_ICF_date": "2021-11-17",
      "eosdt": "2024-09-13",
      "lstcndt": "2024-10-03",
      "FPFV": "2021-11-17",
      "LPLV": "2024-10-03",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2005",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "ADVANCE SC+",
      "Last_Achieved_Milestone": "LSFV",
      "Last_Achieved_Milestones_Long": "Last Subject First Visit",
      "protocol_name": "A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia",
      "days_since_last_adsl_refresh": 24,
      "days_since_last_ae_refresh": 5,
      "days_between": -19,
      "ord": 1,
      "ae_refresh_dt": "2024-10-05",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ZL-1103-013",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "ln",
      "study": "argx-113-2202",
      "sdtm_ae_refresh_date": "2024-09-21",
      "adsl_refresh_date": "2024-09-21",
      "Trial_Title": "A MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EFGARTIGIMOD IN CHINESE PATIENTS WITH LUPUS NEPHRITIS",
      "No_of_subjects_treated": 51,
      "First_ICF_date": "2023-02-21",
      "eosdt": "2024-09-12",
      "lstcndt": "2024-09-19",
      "FPFV": "2023-02-21",
      "LPLV": "2024-09-19",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.5",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ZL-1103-013",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "FSFV",
      "Last_Achieved_Milestones_Long": "First Subject First Visit",
      "protocol_name": "ZAI (ZL-1103-013 ) A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis",
      "days_since_last_adsl_refresh": 38,
      "days_since_last_ae_refresh": 38,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": "2024-08-31",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2002",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2002",
      "sdtm_ae_refresh_date": "2024-10-24",
      "adsl_refresh_date": "2024-10-11",
      "Trial_Title": "A LONG-TERM, SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE 3 STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF MULTIPLE SUBCUTANEOUS INJECTIONS OF EFGARTIGIMOD PH20 SC IN",
      "No_of_subjects_treated": 180,
      "First_ICF_date": "2021-04-26",
      "eosdt": "2024-09-02",
      "lstcndt": "2024-10-01",
      "FPFV": "2021-04-26",
      "LPLV": "2024-10-01",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2002",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "ADAPT SC+",
      "Last_Achieved_Milestone": "LSFV",
      "Last_Achieved_Milestones_Long": "Last Subject First Visit",
      "protocol_name": "A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis.",
      "days_since_last_adsl_refresh": 18,
      "days_since_last_ae_refresh": 5,
      "days_between": -13,
      "ord": 1,
      "ae_refresh_dt": "2024-10-11",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2003",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2003",
      "sdtm_ae_refresh_date": "2024-10-24",
      "adsl_refresh_date": "2024-10-08",
      "Trial_Title": "A PHASE 3B, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE DIFFERENT DOSING REGIMENS OF INTRAVENOUS EFGARTIGIMOD TO MAXIMIZE AND MAINTAIN CLINICAL BENEFIT IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS",
      "No_of_subjects_treated": 69,
      "First_ICF_date": "2021-12-16",
      "eosdt": "2024-09-19",
      "lstcndt": "2024-10-08",
      "FPFV": "2021-12-16",
      "LPLV": "2024-09-30",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "ACTIVE C49649",
      "STUDYID": "ARGX-113-2003",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "ADAPT NXT",
      "Last_Achieved_Milestone": "LSFV",
      "Last_Achieved_Milestones_Long": "Last Subject First Visit",
      "protocol_name": "A Phase 3b, Randomized, Open-Label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis",
      "days_since_last_adsl_refresh": 21,
      "days_since_last_ae_refresh": 5,
      "days_between": -16,
      "ord": 1,
      "ae_refresh_dt": "2024-10-08",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2006",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2006",
      "sdtm_ae_refresh_date": "2024-10-24",
      "adsl_refresh_date": "2024-10-08",
      "Trial_Title": "OPEN-LABEL UNCONTROLLED TRIAL TO EVALUATE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND ACTIVITY OF EFGARTIGIMOD IN CHILDREN FROM 2 TO LESS THAN 18 YEARS OF AGE WITH GENERALIZED MYASTHENIA GRAVIS",
      "No_of_subjects_treated": 13,
      "First_ICF_date": "2021-12-02",
      "eosdt": "2024-05-01",
      "lstcndt": "2024-10-02",
      "FPFV": "2021-10-26",
      "LPLV": "2024-10-02",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "1",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2006",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "ADAPT JR",
      "Last_Achieved_Milestone": "FSFV",
      "Last_Achieved_Milestones_Long": "First Subject First Visit",
      "protocol_name": "Open-label uncontrolled trial to evaluate pharmacokinetics, pharmacodynamics, safety and activity of efgartigimod in children from 2 to less than 18 years of age with generalized myasthenia gravis",
      "days_since_last_adsl_refresh": 21,
      "days_since_last_ae_refresh": 5,
      "days_between": -16,
      "ord": 1,
      "ae_refresh_dt": "2024-10-08",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2008",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2008",
      "sdtm_ae_refresh_date": "2024-10-24",
      "adsl_refresh_date": "2024-10-08",
      "Trial_Title": "A LONG-TERM, SINGLE-ARM, OPEN-LABEL, MULTICENTER TRIAL TO EVALUATE SAFETY OF EFGARTIGIMOD ADMINISTERED INTRAVENOUSLY AND EFGARTIGIMOD PH20 ADMINISTERED SUBCUTANEOUSLY IN CHILDREN WITH GENERALIZED MYASTHENIA GRAVIS",
      "No_of_subjects_treated": 8,
      "First_ICF_date": "2022-08-18",
      "eosdt": "2024-07-24",
      "lstcndt": "2024-09-30",
      "FPFV": "2022-08-18",
      "LPLV": "2024-09-30",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "1",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2008",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "ADAPT JR.+",
      "Last_Achieved_Milestone": "FSFV",
      "Last_Achieved_Milestones_Long": "First Subject First Visit",
      "protocol_name": "A Long-term, Single-Arm, Open-label, Multicenter, Follow-on Trial of ARGX-113-2006 to Evaluate Safety of Efgartigimod Administered Intravenously in Children With Generalized  Myasthenia Gravis",
      "days_since_last_adsl_refresh": 21,
      "days_since_last_ae_refresh": 5,
      "days_between": -16,
      "ord": 1,
      "ae_refresh_dt": "2024-10-08",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2308",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2308",
      "sdtm_ae_refresh_date": "2024-10-25",
      "adsl_refresh_date": "2024-10-25",
      "Trial_Title": "A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 3, PARALLEL GROUP DESIGN STUDY EVALUATING THE EFFICACY AND SAFETY OF EFGARTIGIMOD IV IN ADULT PARTICIPANTS WITH ACETYLCHOLINE RECEPTOR BINDING ANTIBODY (ACHR-AB) SERONEGATIVE GENERALIZED MYASTHENIA GRAVIS (GMG).",
      "No_of_subjects_treated": 0,
      "First_ICF_date": "2024-04-18",
      "eosdt": "2024-09-19",
      "lstcndt": "2024-10-02",
      "FPFV": "2024-04-18",
      "LPLV": "2024-10-02",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "ARGX-113-2308",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "ADAPT SERON",
      "Last_Achieved_Milestone": "FSFV",
      "Last_Achieved_Milestones_Long": "First Subject First Visit",
      "protocol_name": "A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG).",
      "days_since_last_adsl_refresh": 4,
      "days_since_last_ae_refresh": 4,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": "2024-10-05",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ZL-1103-014",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "mn",
      "study": "argx-113-2203",
      "sdtm_ae_refresh_date": "2024-10-28",
      "adsl_refresh_date": "2024-10-29",
      "Trial_Title": "A MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EFGARTIGIMOD IN CHINESE PATIENTS WITH PRIMARY MEMBRANOUS NEPHROPATHY",
      "No_of_subjects_treated": 49,
      "First_ICF_date": "2023-02-20",
      "eosdt": "2024-10-08",
      "lstcndt": "2024-10-08",
      "FPFV": "2023-02-20",
      "LPLV": "2024-10-08",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.5",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ZL-1103-014",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "LSLV",
      "Last_Achieved_Milestones_Long": "Last Subject Last Visit",
      "protocol_name": "ZAI (ZL-1103-014) A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Efgartigimod in Chinese Patients With Primary Membranous Nephropathy",
      "days_since_last_adsl_refresh": 0,
      "days_since_last_ae_refresh": 1,
      "days_between": 1,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2105",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "pots",
      "study": "argx-113-2105",
      "sdtm_ae_refresh_date": "2024-10-24",
      "adsl_refresh_date": "2024-10-01",
      "Trial_Title": "OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN ADULT PATIENTS WITH POST-COVID-19 POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (PC-POTS) WHO COMPLETED STUDY ARGX-113-2105",
      "No_of_subjects_treated": 33,
      "First_ICF_date": "2023-06-26",
      "eosdt": "2024-08-26",
      "lstcndt": "2024-08-26",
      "FPFV": "2023-06-26",
      "LPLV": "2024-08-15",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "1",
      "Control_Type": "NA",
      "STUDYID": "ARGX-113-2105",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "LSFV",
      "Last_Achieved_Milestones_Long": "Last Subject First Visit",
      "protocol_name": "Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104",
      "days_since_last_adsl_refresh": 28,
      "days_since_last_ae_refresh": 5,
      "days_between": -23,
      "ord": 1,
      "ae_refresh_dt": "2024-10-01",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2211",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "sjogren",
      "study": "argx-113-2211",
      "sdtm_ae_refresh_date": "2024-10-24",
      "adsl_refresh_date": "2024-10-25",
      "Trial_Title": "OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF EFGARTIGIMOD IN ADULT PATIENTS WITH PRIMARY SJOEGREN'S SYNDROME (PSS) WHO COMPLETE QUALIFYING EFGARTIGIMOD PSS STUDIES",
      "No_of_subjects_treated": 24,
      "First_ICF_date": "2023-11-29",
      "eosdt": "2024-09-17",
      "lstcndt": "2024-10-11",
      "FPFV": "2023-11-29",
      "LPLV": "2024-10-11",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2211",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "LSFV",
      "Last_Achieved_Milestones_Long": "Last Subject First Visit",
      "protocol_name": "Quincy Model - Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients with primary Sjogrens Syndrome (pSS) who complete qualifying efgartigimod pSS studies",
      "days_since_last_adsl_refresh": 4,
      "days_since_last_ae_refresh": 5,
      "days_between": 1,
      "ord": 1,
      "ae_refresh_dt": "2024-09-18",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "ted",
      "study": "argx-113-2301",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "A PHASE 3, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, DURABILITY, PHARMACODYNAMICS, PHARMACOKINETICS, AND IMMUNOGENICITY OF EFGARTIGIMOD PH20 SC ADMINISTERED BY PREFILLED SYRINGE (PFS) IN ADULT PARTICIPANTS WITH ACTIVE THYROID EYE DISEASE",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "UplighTED",
      "Last_Achieved_Milestone": "FSFV",
      "Last_Achieved_Milestones_Long": "First Subject First Visit",
      "protocol_name": "A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2309",
      "status": "ongoing",
      "product": "argx-113",
      "indication": "ted",
      "study": "argx-113-2309",
      "sdtm_ae_refresh_date": "2024-10-24",
      "adsl_refresh_date": "2024-10-25",
      "Trial_Title": "A PHASE 3, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF EFGARTIGIMOD PH20 SC ADMINISTERED BY PREFILLED SYRINGE IN ADULT PARTICIPANTS WITH THYROID EYE DISEASE",
      "No_of_subjects_treated": 0,
      "First_ICF_date": "2024-06-13",
      "eosdt": "2024-09-24",
      "lstcndt": "2024-10-02",
      "FPFV": "2024-06-13",
      "LPLV": "2024-10-01",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-2309",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "UplighTED",
      "Last_Achieved_Milestone": "FSFV",
      "Last_Achieved_Milestones_Long": "First Subject First Visit",
      "protocol_name": "A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease",
      "days_since_last_adsl_refresh": 4,
      "days_since_last_ae_refresh": 5,
      "days_between": 1,
      "ord": 1,
      "ae_refresh_dt": "2024-10-08",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-117-2201",
      "status": "ongoing",
      "product": "argx-117",
      "indication": "dgf",
      "study": "argx-117-2201",
      "sdtm_ae_refresh_date": "2024-10-01",
      "adsl_refresh_date": "2024-10-01",
      "Trial_Title": "A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, EFFICACY, AND TOLERABILITY OF ARGX-117 IN IMPROVING ALLOGRAFT FUNCTION IN RECIPIENTS OF A DECEASED DO",
      "No_of_subjects_treated": 17,
      "First_ICF_date": "2024-02-16",
      "eosdt": "2024-08-26",
      "lstcndt": "2024-09-18",
      "FPFV": "2023-11-03",
      "LPLV": "2024-09-18",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.5",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-117-2201",
      "Investigational_Treatment": "EMPASIPRUBART PVA73UA67L",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "VARVARA",
      "Last_Achieved_Milestone": "FSFV",
      "Last_Achieved_Milestones_Long": "First Subject First Visit",
      "protocol_name": "A Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of ARGX-117 in Improving Allograft Function in Recipients of a Deceased Donor Renal Allograft at Risk for Delayed Graft Function.",
      "days_since_last_adsl_refresh": 28,
      "days_since_last_ae_refresh": 28,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "",
      "status": "ongoing",
      "product": "argx-117",
      "indication": "dm",
      "study": "argx-117-2301",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "A PHASE 2, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, \nMULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY \nOF EMPASIPRUBART IN ADULTS WITH DERMATOMYOSITIS",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "empacific",
      "Last_Achieved_Milestone": "FSFV",
      "Last_Achieved_Milestones_Long": "First Subject First Visit",
      "protocol_name": "A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, \nMulticenter Study to Evaluate the Safety, Tolerability, and Efficacy \nof Empasiprubart in Adults With Dermatomyositis",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-117-2303",
      "status": "ongoing",
      "product": "argx-117",
      "indication": "hv",
      "study": "argx-117-2303",
      "sdtm_ae_refresh_date": "2024-06-12",
      "adsl_refresh_date": "2024-06-12",
      "Trial_Title": "A PHASE 1, OPEN-LABEL, RANDOMIZED, PARALLEL-GROUP STUDY TO ASSESS THE ABSOLUTE BIOAVAILABILITY OF EMPASIPRUBART SC IN HEALTHY PARTICIPANTS",
      "No_of_subjects_treated": 24,
      "First_ICF_date": "2024-03-11",
      "eosdt": null,
      "lstcndt": "2024-05-24",
      "FPFV": "2024-03-11",
      "LPLV": "2024-05-24",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "ACTIVE C49649",
      "STUDYID": "ARGX-117-2303",
      "Investigational_Treatment": "EMPASIPRUBART PVA73UA67L",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "LSFV",
      "Last_Achieved_Milestones_Long": "Last Subject First Visit",
      "protocol_name": "A Phase 1, Open-label, Randomized, Parallel-group Study to Assess the Absolute Bioavailability of Empasiprubart SC in Healthy Participants",
      "days_since_last_adsl_refresh": 139,
      "days_since_last_ae_refresh": 139,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-117-2003",
      "status": "ongoing",
      "product": "argx-117",
      "indication": "mmn",
      "study": "argx-117-2003",
      "sdtm_ae_refresh_date": "2024-10-25",
      "adsl_refresh_date": "2024-10-02",
      "Trial_Title": "A LONG-TERM EXTENSION OF THE ARGX-117-2002 TRIAL TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY, EFFICACY, PHARMACODYNAMICS, PHARMACOKINETICS, AND IMMUNOGENICITY OF ARGX-117 IN ADULTS WITH MULTIFOCAL MOTOR NEUROPATHY",
      "No_of_subjects_treated": 51,
      "First_ICF_date": "2023-01-18",
      "eosdt": "2024-05-23",
      "lstcndt": "2024-09-24",
      "FPFV": "2023-01-18",
      "LPLV": "2024-09-24",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "ACTIVE C49649",
      "STUDYID": "ARGX-117-2003",
      "Investigational_Treatment": "EMPASIPRUBART PVA73UA67L",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "ARDA+",
      "Last_Achieved_Milestone": "LSFV",
      "Last_Achieved_Milestones_Long": "Last Subject First Visit",
      "protocol_name": "An Open-label Long Term Extension of the ARGX-117-2002 trial to Evaluate the Long-Term Safety and Tolerability and Efficacy of ARGX-117 in Adults With Multifocal Motor Neuropathy",
      "days_since_last_adsl_refresh": 27,
      "days_since_last_ae_refresh": 4,
      "days_between": -23,
      "ord": 1,
      "ae_refresh_dt": "2024-10-02",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-117-2202",
      "status": "ongoing",
      "product": "argx-117",
      "indication": "mmn",
      "study": "argx-117-2202",
      "sdtm_ae_refresh_date": "2024-10-25",
      "adsl_refresh_date": "2024-10-15",
      "Trial_Title": "A MULTICENTER PROSPECTIVE LONGITUDINAL STUDY OF CLINICAL OUTCOMES, DISEASE COURSE, HEALTH-RELATED QUALITY OF LIFE, AND HEALTH CARE RESOURCE UTILIZATION IN ADULT PATIENTS WITH MULTIFOCAL MOTOR NEUROPATHY",
      "No_of_subjects_treated": 0,
      "First_ICF_date": "2023-11-29",
      "eosdt": "2024-06-24",
      "lstcndt": "2024-10-10",
      "FPFV": "2023-11-29",
      "LPLV": "2024-10-10",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-117-2202",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "IMMERSION",
      "Last_Achieved_Milestone": "FSFV",
      "Last_Achieved_Milestones_Long": "First Subject First Visit",
      "protocol_name": "A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health-Related Quality of Life, and Health Care Resource Utilization in Adult Patients With Multifocal Motor Neuropathy",
      "days_since_last_adsl_refresh": 14,
      "days_since_last_ae_refresh": 4,
      "days_between": -10,
      "ord": 1,
      "ae_refresh_dt": "2024-10-15",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-119-NIS-2301",
      "status": "ongoing",
      "product": "argx-119",
      "indication": "cms",
      "study": "argx-119-2301",
      "sdtm_ae_refresh_date": "2024-10-25",
      "adsl_refresh_date": "2024-10-25",
      "Trial_Title": "MULTICENTER, MULTINATIONAL, NATURAL HISTORY STUDY IN PARTICIPANTS WITH DOK7 CONGENITAL MYASTHENIC SYNDROMES",
      "No_of_subjects_treated": 0,
      "First_ICF_date": "2024-02-13",
      "eosdt": "2024-10-02",
      "lstcndt": "2024-10-04",
      "FPFV": "2024-02-13",
      "LPLV": "2024-10-04",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-119-NIS-2301",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "CMS",
      "Last_Achieved_Milestone": "FSFV",
      "Last_Achieved_Milestones_Long": "First Subject First Visit",
      "protocol_name": "Multicenter, Multinational Natural History Study in Participants with DOK7 Congenital Myasthenic Syndrome",
      "days_since_last_adsl_refresh": 4,
      "days_since_last_ae_refresh": 4,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-119-2302",
      "status": "ongoing",
      "product": "argx-119",
      "indication": "cms",
      "study": "argx-119-2302",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": "2024-10-29",
      "Trial_Title": "A PHASE 1B, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, IMMUNOGENICITY, AND EFFICACY OF ARGX-119 IN ADULT PARTICIPANTS WITH DOK7 CONGENITAL MYASTHENIC SYNDROMES",
      "No_of_subjects_treated": 3,
      "First_ICF_date": "2024-09-26",
      "eosdt": null,
      "lstcndt": "2024-10-25",
      "FPFV": "2024-09-25",
      "LPLV": "2024-10-25",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "0.25",
      "Control_Type": "",
      "STUDYID": "ARGX-119-2302",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "FSFV",
      "Last_Achieved_Milestones_Long": "First Subject First Visit",
      "protocol_name": "A Phase 1b, Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Adult Participants With DOK7 Congenital Myasthenic Syndromes",
      "days_since_last_adsl_refresh": 0,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "",
      "status": "planning",
      "product": "argx-113",
      "indication": "sjogren",
      "study": "argx-113-2306",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "QUINCY MODEL - A PHASE 3 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED MULTICENTER TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF EFGARTIGIMOD PH20 SUBCUTANEOUS ADMINISTERED BY PREFILLED SYRINGE IN ADULT PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "",
      "Last_Achieved_Milestone": "PA",
      "Last_Achieved_Milestones_Long": "Protocol Approval",
      "protocol_name": "Quincy Model - A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Syndrome",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 2,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "",
      "status": "startup",
      "product": "argx-113",
      "indication": "amr",
      "study": "argx-113-2302",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "A MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD IN KIDNEY TRANSPLANT RECIPIENTS WITH ANTIBODY MEDIATED REJECTION.",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "shAMRock",
      "Last_Achieved_Milestone": "FSA",
      "Last_Achieved_Milestones_Long": "First Site Activated",
      "protocol_name": "A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod in Kidney Transplant Recipients With Antibody Mediated Rejection.",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "",
      "status": "startup",
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2207",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "AN OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND ACTIVITY OF EFGARTIGIMOD PH20 SC IN PARTICIPANTS FROM 2 TO LESS THAN 18 YEARS OF AGE WITH GENERALIZED MYASTHENIA GRAVIS",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "ADAPT JR SC",
      "Last_Achieved_Milestone": "FSA",
      "Last_Achieved_Milestones_Long": "First Site Activated",
      "protocol_name": "An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "",
      "status": "startup",
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2315",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 3, PARALLEL-GROUP DESIGN STUDY EVALUATING THE EFFICACY AND SAFETY OF EFGARTIGIMOD PH20 SC ADMINISTERED BY PREFILLED SYRINGE IN ADULT PARTICIPANTS WITH OCULAR MYASTHENIA GRAVIS",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "ADAPT Oculus",
      "Last_Achieved_Milestone": "FSA",
      "Last_Achieved_Milestones_Long": "First Site Activated",
      "protocol_name": "A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "",
      "status": "startup",
      "product": "argx-119",
      "indication": "als",
      "study": "argx-119-2303",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "A PHASE 2A, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED, AND ACTIVE-TREATMENT EXTENSION STUDY TO ASSESS THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY OF ARGX-119 IN PARTICIPANTS WITH AMYOTROPHIC LATERAL SCLEROSIS",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "ReALiSe",
      "Last_Achieved_Milestone": "FSA",
      "Last_Achieved_Milestones_Long": "First Site Activated",
      "protocol_name": "A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants With Amyotrophic Lateral Sclerosis",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "",
      "status": "unknown",
      "product": "argx-113",
      "indication": "aav",
      "study": "argx-113-2212",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "",
      "Last_Achieved_Milestone": "",
      "Last_Achieved_Milestones_Long": "",
      "protocol_name": "",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 4,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "",
      "status": "unknown",
      "product": "argx-113",
      "indication": "aav",
      "study": "argx-113-2213",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "",
      "Last_Achieved_Milestone": "",
      "Last_Achieved_Milestones_Long": "",
      "protocol_name": "",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 4,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "",
      "status": "unknown",
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2101",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "",
      "Last_Achieved_Milestone": "",
      "Last_Achieved_Milestones_Long": "",
      "protocol_name": "",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 4,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "",
      "status": "unknown",
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-pac-2314",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "",
      "Last_Achieved_Milestone": "",
      "Last_Achieved_Milestones_Long": "",
      "protocol_name": "",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 4,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "",
      "status": "unknown",
      "product": "argx-113",
      "indication": "ted",
      "study": "argx-113-2310",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "",
      "Last_Achieved_Milestone": "",
      "Last_Achieved_Milestones_Long": "",
      "protocol_name": "",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 4,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "",
      "status": "unknown",
      "product": "argx-117",
      "indication": "covid-19",
      "study": "argx-117-2001",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": null,
      "dbl_status": "",
      "Study_Name": "",
      "Last_Achieved_Milestone": "",
      "Last_Achieved_Milestones_Long": "",
      "protocol_name": "",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 4,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-1802",
      "status": "final",
      "product": "argx-113",
      "indication": "cidp",
      "study": "argx-113-1802",
      "sdtm_ae_refresh_date": "2024-03-20",
      "adsl_refresh_date": "2024-08-03",
      "Trial_Title": "A PHASE 2 TRIAL TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF EFGARTIGIMOD PH20 SC IN ADULT PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)",
      "No_of_subjects_treated": 322,
      "First_ICF_date": "2020-04-15",
      "eosdt": "2023-05-11",
      "lstcndt": "2023-05-23",
      "FPFV": "2020-04-15",
      "LPLV": "2023-05-11",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.5",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-1802",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2023-11-21",
      "csr_status": "final",
      "dbl_date": "2023-06-22",
      "dbl_status": "final",
      "Study_Name": "ADHERE",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "days_since_last_adsl_refresh": 87,
      "days_since_last_ae_refresh": 223,
      "days_between": 136,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-1501",
      "status": "final",
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-1501",
      "sdtm_ae_refresh_date": "2021-12-17",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "A PAHSE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING INTRAVENOUS DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND IMMUNOGENICITY OF ARGX-113 IN HEALTHY MALES AND FEMALE SUBJECTS OF NON-CHILD BEARING POTENTIAL.",
      "No_of_subjects_treated": 62,
      "First_ICF_date": "2015-09-30",
      "eosdt": "2016-10-14",
      "lstcndt": "2016-10-14",
      "FPFV": "2015-09-30",
      "LPLV": "2016-10-14",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-1501",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2017-02-21",
      "csr_status": "final",
      "dbl_date": "2016-11-14",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ARGX-113 in Healthy Males and Female Subjects of Non-Child Bearing Potential",
      "days_since_last_adsl_refresh": 459,
      "days_since_last_ae_refresh": 1047,
      "days_between": 588,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-1702",
      "status": "final",
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-1702",
      "sdtm_ae_refresh_date": "2022-02-03",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "A RANDOMIZED, OPEN-LABEL,PARALLEL GROUP STUDY TO COMPARE THE PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY AND TOLERABILITY OF A SUBCUTANEOUS FORMULATION WITH AN INTRAVENOUS FORMULATION OF ARGX-113 IN HEALTHY MALE SUBJECTS",
      "No_of_subjects_treated": 40,
      "First_ICF_date": "2017-10-27T11:10",
      "eosdt": "2018-09-19",
      "lstcndt": "2018-09-19",
      "FPFV": "2017-10-16T11:35",
      "LPLV": "2018-09-19",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "ACTIVE",
      "STUDYID": "ARGX-113-1702",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "csr_date": "2019-04-16",
      "csr_status": "final",
      "dbl_date": "2018-10-19",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Randomized, Open-label, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of a Subcutaneous Formulation with an Intravenous Formulation of ARGX-113 in Healthy Male Subjects",
      "days_since_last_adsl_refresh": 459,
      "days_since_last_ae_refresh": 999,
      "days_between": 540,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-1901",
      "status": "final",
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-1901",
      "sdtm_ae_refresh_date": "2022-07-01",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "A PHASE 1, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP TRIAL TO INVESTIGATE THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF DIFFERENT SINGLE SUBCUTANEOUS DOSE LEVELS OF EFGARTIGIMOD CO-ADMINISTERED WITH RHUPH20 IN HEALTHY ADULT MALE SUBJECTS",
      "No_of_subjects_treated": 33,
      "First_ICF_date": "2019-07-01",
      "eosdt": "2019-10-04",
      "lstcndt": "2019-10-04",
      "FPFV": "2019-07-01",
      "LPLV": "2019-10-04",
      "SDTM_IG_Version": "3.2",
      "SDTM_Version": "1.4",
      "Randomization_Quotient": "1.00",
      "Control_Type": "DOSE RESPONSE C120841",
      "STUDYID": "ARGX-113-1901",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "HYALURONIDASE (HUMAN RECOMBINANT) 743QUY4VD8",
      "csr_date": "2020-03-20",
      "csr_status": "final",
      "dbl_date": "2019-11-11",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Phase 1, Randomized, Open-label, Parallel-group Trial to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Different Single Subcutaneous Dose Levels of Efgartigimod Co-administered with rHuPH20 in Healthy Adult Male Subjects",
      "days_since_last_adsl_refresh": 459,
      "days_since_last_ae_refresh": 851,
      "days_between": 392,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-1907",
      "status": "final",
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-1907",
      "sdtm_ae_refresh_date": "2022-07-01",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "A PHASE 1, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY TO COMPARE THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF MULTIPLE INTRAVENOUS INFUSIONS OF EFGARTIGIMOD WITH MULTIPLE SUBCUTANEOUS INJECTIONS OF EFGARTIGIMOD PH20 SC IN HEALTHY SUBJECTS",
      "No_of_subjects_treated": 54,
      "First_ICF_date": "2020-08-18",
      "eosdt": "2021-02-11",
      "lstcndt": "2021-02-12",
      "FPFV": "2020-08-18",
      "LPLV": "2021-02-11",
      "SDTM_IG_Version": "3.2",
      "SDTM_Version": "1.4",
      "Randomization_Quotient": "1",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-1907",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2021-09-14",
      "csr_status": "final",
      "dbl_date": "2021-03-11",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Phase 1, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Multiple Intravenous Infusions of Efgartigimod With Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Healthy Subjects",
      "days_since_last_adsl_refresh": 459,
      "days_since_last_ae_refresh": 851,
      "days_between": 392,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2102",
      "status": "final",
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-2102",
      "sdtm_ae_refresh_date": "2023-04-13",
      "adsl_refresh_date": "2023-07-10",
      "Trial_Title": "A RANDOMIZED, OPEN-LABEL, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE IMMUNE RESPONSE TO THE POLYVALENT PNEUMOCOCCAL VACCINE (PNEUMOVAX 23) IN HEALTHY PARTICIPANTS RECEIVING INTRAVENOUS EFGARTIGIMOD OR PLACEBO",
      "No_of_subjects_treated": 36,
      "First_ICF_date": "2021-11-17",
      "eosdt": "2022-03-08",
      "lstcndt": "2022-03-08",
      "FPFV": "2021-11-17",
      "LPLV": "2022-03-08",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.67",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-2102",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2022-11-30",
      "csr_status": "final",
      "dbl_date": "2022-04-11",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Randomized, Open-label, Placebo-Controlled, Parallel-Group Study to Evaluate the Immune Response to the Polyvalent Pneumococcal Vaccine (PNEUMOVAX 23) in Healthy Participants Receiving Intravenous Efgartigimod or Placebo",
      "days_since_last_adsl_refresh": 477,
      "days_since_last_ae_refresh": 565,
      "days_between": 88,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2201",
      "status": "final",
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-2201",
      "sdtm_ae_refresh_date": "2024-09-21",
      "adsl_refresh_date": "2024-09-21",
      "Trial_Title": "A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS OF EFGARTIGIMOD IV 10 MG/KG SINGLE DOSE ADMINISTERED IN PARTICIPANTS WITH RENAL IMPAIRMENT",
      "No_of_subjects_treated": 33,
      "First_ICF_date": "2023-07-19T08:50",
      "eosdt": "2024-06-12",
      "lstcndt": "2024-06-12",
      "FPFV": "2023-07-19",
      "LPLV": "2024-06-12",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2201",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": "2024-08-08",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "DBL",
      "Last_Achieved_Milestones_Long": "Database Lock",
      "protocol_name": "A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics of Efgartigimod IV 10mg/kg Single Dose Administered in Participants With Renal Impairment",
      "days_since_last_adsl_refresh": 38,
      "days_since_last_ae_refresh": 38,
      "days_between": 0,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2204",
      "status": "final",
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-2204",
      "sdtm_ae_refresh_date": "2024-02-20",
      "adsl_refresh_date": "2024-02-20",
      "Trial_Title": "A PHASE 1, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, SINGLE-DOSE, BIOEQUIVALENCE STUDY OF EFGARTIGIMOD PH20 SC ADMINISTERED VIA A PREFILLED SYRING VERSUS A VIAL + SYRINGE PRESENTATION IN HEALTHY ADULTS",
      "No_of_subjects_treated": 120,
      "First_ICF_date": "2023-03-02",
      "eosdt": "2023-06-30",
      "lstcndt": "2023-06-30",
      "FPFV": "2023-03-02",
      "LPLV": "2023-06-30",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "ACTIVE C49649",
      "STUDYID": "ARGX-113-2204",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2024-04-30",
      "csr_status": "final",
      "dbl_date": "2023-07-20",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Phase 1, Randomized, Open-label, Parallel-Group, Single-Dose, Bioequivalence Study of Efgartigimod PH20 SC Administered via a Prefilled Syringe Versus a Viral-Syringe Presentation in Healthy Adults",
      "days_since_last_adsl_refresh": 252,
      "days_since_last_ae_refresh": 252,
      "days_between": 0,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2303",
      "status": "final",
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-2303",
      "sdtm_ae_refresh_date": "2024-04-06",
      "adsl_refresh_date": "2024-04-08",
      "Trial_Title": "A PHASE 1, SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY IN HEALTHY ADULTS TO ASSESS THE FEASIBILITY OF DIFFERENT SPEEDS OF SUBCUTANEOUS INJECTION FOR EFGARTIGIMOD PH20 SC",
      "No_of_subjects_treated": 48,
      "First_ICF_date": "2023-08-16T09:17",
      "eosdt": "2023-12-06",
      "lstcndt": "2023-12-06",
      "FPFV": "2023-08-16",
      "LPLV": "2023-12-06",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.384",
      "Control_Type": "DOSE RESPONSE C120841",
      "STUDYID": "ARGX-113-2303",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2024-06-25",
      "csr_status": "final",
      "dbl_date": "2024-01-12",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Phase 1, Single-Center, Randomized, Open-Label, Crossover  Study in Healthy Adults to Assess the Feasibility of Different Speeds of Subcutaneous Injection for Efgartigimod PH20 SC",
      "days_since_last_adsl_refresh": 204,
      "days_since_last_ae_refresh": 206,
      "days_between": 2,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2312",
      "status": "final",
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-2312",
      "sdtm_ae_refresh_date": "2024-03-27",
      "adsl_refresh_date": "2024-03-28",
      "Trial_Title": "A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, 2-PERIOD CROSS-OVER, BIOEQUIVALENCE STUDY OF EFGARTIGIMOD PH20 SC ADMINSTERED VIA A PREFILLED SYRINGE VERSUS A VIAL + SYRINGE PRESENTATION IN HEALTHY PARTICIPANTS",
      "No_of_subjects_treated": 72,
      "First_ICF_date": "2023-10-21",
      "eosdt": "2024-02-12",
      "lstcndt": "2024-02-12",
      "FPFV": "2023-10-21",
      "LPLV": "2024-02-12",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "ACTIVE C49649",
      "STUDYID": "ARGX-113-2312",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2024-05-13",
      "csr_status": "final",
      "dbl_date": "2024-02-13",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Phase 1, Open-label, Randomized, Single-Dose, Two-Period Cross-Over, Bioequivalence Study of Efgartigimod PH20 SC Administered via a Prefilled Syringe Versus a Vial + Syringe Presentation in Healthy Adults",
      "days_since_last_adsl_refresh": 215,
      "days_since_last_ae_refresh": 216,
      "days_between": 1,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ZL-1103-005, ARGX-113-2103",
      "status": "final",
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-z005",
      "sdtm_ae_refresh_date": "2022-12-16",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE 1 STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF AN INTRAVENOUS FORMULATION OF EFGARTIGIMOD IN HEALTHY C HINESE ADULT SUBJECTS",
      "No_of_subjects_treated": 16,
      "First_ICF_date": "2021-09-22",
      "eosdt": "2021-12-25",
      "lstcndt": "2021-12-25",
      "FPFV": "2021-09-22",
      "LPLV": "2021-12-25",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "0.75",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ZL-1103-005",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2022-05-10",
      "csr_status": "final",
      "dbl_date": "2022-02-01",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "ZAI (ZL-1103-005) A randomized, Double-Blinded, Placebo-Controlled Phase 1 Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of an Intravenous Formulation of Efgartigimod in Healthy Chinese Adult Subjects",
      "days_since_last_adsl_refresh": 459,
      "days_since_last_ae_refresh": 683,
      "days_between": 224,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ZL-1103-006, ARGX-113-2107",
      "status": "final",
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-z006",
      "sdtm_ae_refresh_date": "2022-12-16",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "A RANDOMIZED, DOUBLE-BLINDED AND PLACEBO-CONTROLLED PHASE 1 STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF EFGARTIGIMOD SC CO-FORMULATED WITH RHUPH20 IN HEALTH Y CHINESE ADULT SUBJECTS",
      "No_of_subjects_treated": 16,
      "First_ICF_date": "2021-09-15",
      "eosdt": "2021-12-09",
      "lstcndt": "2021-12-27",
      "FPFV": "2021-09-15",
      "LPLV": "2021-12-27",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "0.75",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ZL-1103-006",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2022-05-10",
      "csr_status": "final",
      "dbl_date": "2022-01-20",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "ZAI (ZL-1103-006) A Randomized, Double-Blinded and Placebo-Controlled Phase 1 Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Efgartigimod SC Co-formulated with rHuPH20 in Healthy Chinese Adult Subjects",
      "days_since_last_adsl_refresh": 459,
      "days_since_last_ae_refresh": 683,
      "days_between": 224,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-1603",
      "status": "final",
      "product": "argx-113",
      "indication": "itp",
      "study": "argx-113-1603",
      "sdtm_ae_refresh_date": "2022-08-17",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ARGX-113 IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA",
      "No_of_subjects_treated": 38,
      "First_ICF_date": "2017-03-14",
      "eosdt": "2018-05-31",
      "lstcndt": "2019-04-09",
      "FPFV": "2017-03-20",
      "LPLV": "2019-04-09",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "0.6",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-1603",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2018-12-14",
      "csr_status": "final",
      "dbl_date": "2018-07-04",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia, followed by an Open-Label Treatment Period",
      "days_since_last_adsl_refresh": 459,
      "days_since_last_ae_refresh": 804,
      "days_between": 345,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-1801",
      "status": "final",
      "product": "argx-113",
      "indication": "itp",
      "study": "argx-113-1801",
      "sdtm_ae_refresh_date": "2023-12-18",
      "adsl_refresh_date": "2024-06-21",
      "Trial_Title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF EFGARTIGIMOD (ARGX-113) 10 MG/KG INTRAVENOUS IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA.",
      "No_of_subjects_treated": 131,
      "First_ICF_date": "2019-12-09",
      "eosdt": "2022-02-03",
      "lstcndt": "2022-02-03",
      "FPFV": "2019-12-09",
      "LPLV": "2022-02-03",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.33",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-1801",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2022-11-16",
      "csr_status": "final",
      "dbl_date": "2022-05-31",
      "dbl_status": "final",
      "Study_Name": "ADVANCE",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia",
      "days_since_last_adsl_refresh": 130,
      "days_since_last_ae_refresh": 316,
      "days_between": 186,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2004",
      "status": "final",
      "product": "argx-113",
      "indication": "itp",
      "study": "argx-113-2004",
      "sdtm_ae_refresh_date": "2024-01-31",
      "adsl_refresh_date": "2024-06-20",
      "Trial_Title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND THE SAFETY OF EFGARTIGIMOD (ARGX-113) PH20 SUBCUTANEOUS IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA",
      "No_of_subjects_treated": 207,
      "First_ICF_date": "2020-12-16",
      "eosdt": "2023-10-09",
      "lstcndt": "2023-10-09",
      "FPFV": "2020-12-16",
      "LPLV": "2023-10-09",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.67",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-2004",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2024-07-31",
      "csr_status": "final",
      "dbl_date": "2023-11-14",
      "dbl_status": "final",
      "Study_Name": "ADVANCE SC",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia",
      "days_since_last_adsl_refresh": 131,
      "days_since_last_ae_refresh": 272,
      "days_between": 141,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-1602",
      "status": "final",
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-1602",
      "sdtm_ae_refresh_date": "2021-01-12",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ARGX-113 IN PATIENTS WITH MYASTHENIA GRAVIS WHO HAVE GENERALIZED MUSCLE WEAKNESS",
      "No_of_subjects_treated": 24,
      "First_ICF_date": "2016-12-30",
      "eosdt": "2017-10-20",
      "lstcndt": "2017-10-20",
      "FPFV": "2017-01-10",
      "LPLV": "2017-10-20",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "0.5",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-1602",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2018-02-13",
      "csr_status": "final",
      "dbl_date": "2017-11-10",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Randomized, Double-blind, Placebo-Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness",
      "days_since_last_adsl_refresh": 459,
      "days_since_last_ae_refresh": 1386,
      "days_between": 927,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-1704",
      "status": "final",
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-1704",
      "sdtm_ae_refresh_date": "2021-12-17",
      "adsl_refresh_date": "2024-04-06",
      "Trial_Title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 3 TRIAL TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ARGX-113 IN PATIENTS WITH MYASTHENIA GRAVIS HAVING GENERALIZED MUSCLE WEA KNESS",
      "No_of_subjects_treated": 167,
      "First_ICF_date": "2018-08-22",
      "eosdt": "2020-04-06",
      "lstcndt": "2020-04-06",
      "FPFV": "2018-08-22",
      "LPLV": "2020-04-06",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "0.5",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-1704",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2020-08-18",
      "csr_status": "final",
      "dbl_date": "2020-05-13",
      "dbl_status": "final",
      "Study_Name": "ADAPT",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis Having Generalized Muscle Weakness",
      "days_since_last_adsl_refresh": 206,
      "days_since_last_ae_refresh": 1047,
      "days_between": 841,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-1705",
      "status": "final",
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-1705",
      "sdtm_ae_refresh_date": "2023-04-14",
      "adsl_refresh_date": "2024-07-26",
      "Trial_Title": "A LONG-TERM, SINGLE-ARM, OPEN-LABEL, MULTICENTER, PHASE 3 FOLLOW-ON TRIAL OF ARGX-113-1704 TO EVALUATE THE SAFETY AND TOLERABILITY OF ARGX-113 IN PATIENTS WITH MYASTHENIA GRAVIS HAVING GENERALIZED MUS CLE WEAKNESS",
      "No_of_subjects_treated": 145,
      "First_ICF_date": "2019-03-01",
      "eosdt": "2022-06-30",
      "lstcndt": "2022-07-20",
      "FPFV": "2019-03-01",
      "LPLV": "2022-06-30",
      "SDTM_IG_Version": "3.2",
      "SDTM_Version": "1.4",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-1705",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2023-03-21",
      "csr_status": "final",
      "dbl_date": "2022-10-29",
      "dbl_status": "final",
      "Study_Name": "ADAPT+",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness",
      "days_since_last_adsl_refresh": 95,
      "days_since_last_ae_refresh": 564,
      "days_between": 469,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2001",
      "status": "final",
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2001",
      "sdtm_ae_refresh_date": "2023-02-20",
      "adsl_refresh_date": "2024-07-26",
      "Trial_Title": "A PHASE 3, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY TO COMPARE THE PHARMACODYNAMICS, PHARMACOKINETICS, EFFICACY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE SUBCUTANEOUS INJECTIONS OF EFGARTIGIMOD PH20 SC WITH MULTIPLE INTRAVENOUS INFUSIONS OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS",
      "No_of_subjects_treated": 110,
      "First_ICF_date": "2021-02-24",
      "eosdt": "2021-12-13",
      "lstcndt": "2022-01-20",
      "FPFV": "2021-02-05",
      "LPLV": "2021-12-13",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2001",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2022-08-16",
      "csr_status": "final",
      "dbl_date": "2022-02-04",
      "dbl_status": "final",
      "Study_Name": "ADAPT SC",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of Efgartigimod PH20 SC With Multiple Intravenous Infusions of Efgartigimod in Patients With Generalized Myasthenia Gravis",
      "days_since_last_adsl_refresh": 95,
      "days_since_last_ae_refresh": 617,
      "days_between": 522,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-1701",
      "status": "final",
      "product": "argx-113",
      "indication": "pemphigus",
      "study": "argx-113-1701",
      "sdtm_ae_refresh_date": "2024-02-27",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "AN OPEN-LABEL, NON-CONTROLLED, PHASE II STUDY TO EVALUATE THE SAFETY, PHARMACODYNAMICS, PHARMACOKINETICS, EFFICACY AND CONDITIONS OF USE OF ARGX-113 IN PATIENTS WITH MILD TO MODERATE PEMPHIGUS (VULGARIS OR FOLIACEUS)",
      "No_of_subjects_treated": 34,
      "First_ICF_date": "2017-11-02",
      "eosdt": "2020-10-28",
      "lstcndt": "2020-10-28",
      "FPFV": "2017-11-02",
      "LPLV": "2020-10-28",
      "SDTM_IG_Version": "3.2",
      "SDTM_Version": "1.4",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-1701",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2021-10-08",
      "csr_status": "final",
      "dbl_date": "2020-12-14",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "An Open-label, Non-controlled, Phase II Study to Evaluate the\nSafety, Pharmacodynamics, Pharmacokinetics, Efficacy and\nConditions of Use of ARGX-113 in Patients with Mild to\nModerate Pemphigus (Vulgaris or Foliaceus)",
      "days_since_last_adsl_refresh": 459,
      "days_since_last_ae_refresh": 245,
      "days_between": -214,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-1904",
      "status": "final",
      "product": "argx-113",
      "indication": "pemphigus",
      "study": "argx-113-1904",
      "sdtm_ae_refresh_date": "2024-06-14",
      "adsl_refresh_date": "2024-06-14",
      "Trial_Title": "A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF EFGARTIGIMOD PH20 SC IN ADULT PATIENTS WITH PEMPHIGUS (VULGARIS OR FOLIACEUS) (ADDRESS).",
      "No_of_subjects_treated": 222,
      "First_ICF_date": "2020-12-14",
      "eosdt": "2023-08-22",
      "lstcndt": "2023-10-16",
      "FPFV": "2020-12-14",
      "LPLV": "2023-08-22",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-1904",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": "2024-07-03",
      "csr_status": "final",
      "dbl_date": "2023-10-27",
      "dbl_status": "final",
      "Study_Name": "ADDRESS",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus)",
      "days_since_last_adsl_refresh": 137,
      "days_since_last_ae_refresh": 137,
      "days_between": 0,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-1905",
      "status": "final",
      "product": "argx-113",
      "indication": "pemphigus",
      "study": "argx-113-1905",
      "sdtm_ae_refresh_date": "2024-06-14",
      "adsl_refresh_date": "2024-07-18",
      "Trial_Title": "AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY OF ARGX-113-1904 TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD PH20 SC IN PATIENTS WITH PEMPHIGUS (ADDRESS+)",
      "No_of_subjects_treated": 149,
      "First_ICF_date": "2021-07-15",
      "eosdt": "2024-03-25",
      "lstcndt": "2024-03-25",
      "FPFV": "2021-07-15",
      "LPLV": "2024-03-25",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-1905",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": "2024-06-07",
      "dbl_status": "final",
      "Study_Name": "ADDRESS+",
      "Last_Achieved_Milestone": "DBL",
      "Last_Achieved_Milestones_Long": "Database Lock",
      "protocol_name": "An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Pemphigus (ADDRESS+)",
      "days_since_last_adsl_refresh": 103,
      "days_since_last_ae_refresh": 137,
      "days_between": 34,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2104",
      "status": "final",
      "product": "argx-113",
      "indication": "pots",
      "study": "argx-113-2104",
      "sdtm_ae_refresh_date": "2024-10-25",
      "adsl_refresh_date": "2024-09-27",
      "Trial_Title": "A PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EFGARTIGIMOD IV IN ADULT PATIENTS WITH POST-COVID-19 POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS)",
      "No_of_subjects_treated": 53,
      "First_ICF_date": "2022-11-01",
      "eosdt": "2024-04-18",
      "lstcndt": "2024-04-18",
      "FPFV": "2022-11-01",
      "LPLV": "2024-04-18",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.5",
      "Randomization_Quotient": "0.67",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-2104",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": "2024-07-15",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "DBL",
      "Last_Achieved_Milestones_Long": "Database Lock",
      "protocol_name": "Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with post–COVID-19 postural orthostatic tachycardia syndrome (POTS)",
      "days_since_last_adsl_refresh": 32,
      "days_since_last_ae_refresh": 4,
      "days_between": -28,
      "ord": 5,
      "ae_refresh_dt": "2024-09-27",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-113-2106",
      "status": "final",
      "product": "argx-113",
      "indication": "sjogren",
      "study": "argx-113-2106",
      "sdtm_ae_refresh_date": "2024-09-07",
      "adsl_refresh_date": "2024-09-07",
      "Trial_Title": "A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOUBLE-BLINDED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS EFGARTIGIMOD IN ADULT PARTICIPANTS WITH PRIMARY SJO EGRENS SYNDROME",
      "No_of_subjects_treated": 34,
      "First_ICF_date": "2023-05-08",
      "eosdt": "2024-02-12",
      "lstcndt": "2024-02-12",
      "FPFV": "2023-05-08",
      "LPLV": "2024-02-12",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.67",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-2106",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": "2024-05-02",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "DBL",
      "Last_Achieved_Milestones_Long": "Database Lock",
      "protocol_name": "Quincy Model - A Phase 2, Randomized, Placebo-Controlled, Parallel-Group, Double-Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Intravenous Efgartigimod in Adult Participants With Primary Sjögren’s Syndrome",
      "days_since_last_adsl_refresh": 52,
      "days_since_last_ae_refresh": 52,
      "days_between": 0,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-117-1901",
      "status": "final",
      "product": "argx-117",
      "indication": "hv",
      "study": "argx-117-1901",
      "sdtm_ae_refresh_date": "2022-12-15",
      "adsl_refresh_date": "2024-02-29",
      "Trial_Title": "A FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL IN HEALTHY SUBJECTS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF SINGLE AND MULTIPLE ASCENDING INTRAVENOUS DOSE LEVELS OF ARGX-117 AND SUBCUTANEOUS DOSE LEVELS OF ARGX-117 CO-MIXED WITH RECOMBINANT HUMAN HYALURONIDASE PH20",
      "No_of_subjects_treated": 109,
      "First_ICF_date": "2020-03-10",
      "eosdt": "2022-08-26",
      "lstcndt": "2022-08-26",
      "FPFV": "2020-03-10",
      "LPLV": "2022-08-26",
      "SDTM_IG_Version": "3.2",
      "SDTM_Version": "1.4",
      "Randomization_Quotient": "0.75",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-117-1901",
      "Investigational_Treatment": "NAV",
      "Investigational_Treatment2": "",
      "csr_date": "2023-05-11",
      "csr_status": "final",
      "dbl_date": "2022-11-09",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "CSR",
      "Last_Achieved_Milestones_Long": "Final Clinical Study Report",
      "protocol_name": "A First-in-Human, Randomized, Double-Blinded, Placebo-Controlled Trial in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Ascending Intravenous Dose Levels of ARGX 117 and Subcutaneous Dose Levels of ARGX-117 Co-Mixed With Recombinant Human Hyaluronidase PH20.",
      "days_since_last_adsl_refresh": 243,
      "days_since_last_ae_refresh": 684,
      "days_between": 441,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-117-2002",
      "status": "final",
      "product": "argx-117",
      "indication": "mmn",
      "study": "argx-117-2002",
      "sdtm_ae_refresh_date": "2024-10-29",
      "adsl_refresh_date": "2024-10-23",
      "Trial_Title": "A PHASE 2, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY",
      "No_of_subjects_treated": 54,
      "First_ICF_date": "2022-03-31",
      "eosdt": "2024-06-04",
      "lstcndt": "2024-06-04",
      "FPFV": "2022-03-31",
      "LPLV": "2024-06-04",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": ".667",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-117-2002",
      "Investigational_Treatment": "EMPASIPRUBART PVA73UA67L",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": "2024-07-18",
      "dbl_status": "final",
      "Study_Name": "ARDA",
      "Last_Achieved_Milestone": "DBL",
      "Last_Achieved_Milestones_Long": "Database Lock",
      "protocol_name": "A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multi-Center Trial to Evaluate the Efficacy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy.",
      "days_since_last_adsl_refresh": 6,
      "days_since_last_ae_refresh": 0,
      "days_between": -6,
      "ord": 5,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "studyid_add": "ARGX-119-2201",
      "status": "final",
      "product": "argx-119",
      "indication": "hv",
      "study": "argx-119-2201",
      "sdtm_ae_refresh_date": "2024-10-24",
      "adsl_refresh_date": "2024-10-25",
      "Trial_Title": "A PHASE 1, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF SINGLE AND MULTIPLE ASCENDING DOSES OF ARGX-119 IN HEALTHY PARTICIPANTS",
      "No_of_subjects_treated": 112,
      "First_ICF_date": "2023-02-03",
      "eosdt": "2024-08-08",
      "lstcndt": "2024-08-08",
      "FPFV": "2023-02-03",
      "LPLV": "2024-08-08",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.74",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-119-2201",
      "Investigational_Treatment": "ARGX-119 FJK85PF3WY",
      "Investigational_Treatment2": "",
      "csr_date": null,
      "csr_status": "",
      "dbl_date": "2024-09-09",
      "dbl_status": "final",
      "Study_Name": "N/A",
      "Last_Achieved_Milestone": "DBL",
      "Last_Achieved_Milestones_Long": "Database Lock",
      "protocol_name": "A First-in-Human, Randomized, Double-Blind, Placebo-Controlled Trial in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Single and Multiple Ascending Intravenous Dose Levels of ARGX-119",
      "days_since_last_adsl_refresh": 4,
      "days_since_last_ae_refresh": 5,
      "days_between": 1,
      "ord": 5,
      "ae_refresh_dt": "2024-10-19",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    }
  ]
}
